Robert A. Rosenheck, MD

Suicide Attempts and Health-Related Quality of Life

February 27, 2023

People with recent suicide attempts have much lower mental health–related QOL than those with no attempt or an attempt in the distant past. Psychiatric and substance use comorbidities explain...

Tanner J. Bommersbach, Robert A. Rosenheck, Taeho Greg Rhee

Original Research

ED Visits for Mental Health Conditions in the US

July 28, 2020

The Affordable Care Act of 2010, implemented in 2014, expanded access to outpatient mental health services, potentially reducing reliance on emergency departments (EDs). This study examined trends in mental...

Kayla M. Theriault, Robert A. Rosenheck, Taeho Greg Rhee

Original Research

Post-Discharge Suicide Attempts in Veterans Treated for PTSD

August 13, 2019

US veterans are at a high risk of suicide, but what specific clinical factors are linked to this risk? This study of veterans discharged from PTSD programs examined the...

Elina A. Stefanovics, Robert A. Rosenheck

Original Research

Heterogeneity of Treatment Effects of LAI Antipsychotics

November 27, 2018

Which subgroups of patients with schizophrenia or schizoaffective disorder may be prone to treatment failure? Is it men or women, old or young, or are more factors involved? Researchers...

T. Scott Stroup, Natalie A. Bareis, Robert A. Rosenheck, et al

Original Research

Antipsychotic Prescriptions in Outpatients With MDD

February 13, 2018

Because recent research supports the effectiveness of antipsychotics in nonresponsive major depressive disorder, examining national prescribing trends for these drugs in MDD is a timely topic. Using data from...

Taeho Greg Rhee, Somaia Mohamed, Robert A. Rosenheck

Commentary

Benzodiazepine Safety: Mortality Risk or Multiple Chronic Disease Comorbidity?

May 25, 2016

Robert A. Rosenheck, Mehmet Sofuoglu

Original Research

Sleep Disturbance in Chronic Military-Related PTSD: Clinical Impact and Response to Adjunctive Risperidone in the Veterans Affairs Cooperative Study #504

April 27, 2016

John H. Krystal, Robert H. Pietrzak, Robert A. Rosenheck, et al

Article

Marijuana Use Is Associated With Worse Outcomes in Symptom Severity and Violent Behavior in Patients With Posttraumatic Stress Disorder

September 23, 2015

Samuel T. Wilkinson, Elina Stefanovics, Robert A. Rosenheck

Original Research

The RAISE: First-Episode Psychosis

March 25, 2015

Read an article describing The RAISE Early Treatment Program for First-Episode Psychosis, the background and study design of the program.

John M. Kane, Nina R. Schooler, Patricia Marcy, et al

Letter to the Editor

Reply to Cost and Cost-Effectiveness in a Randomized Trial of Long-Acting Risperidone for Schizophrenia

October 15, 2012

Paul G. Barnett, Robert A. Rosenheck

Original Research

Cost and Cost-Effectiveness in a Randomized Trial of Long-Acting Risperidone for Schizophrenia

May 15, 2012

Paul G. Barnett, Jennifer Y. Scott, John H. Krystal, et al

Article

Minimum Clinically Important Difference in the Positive and Negative Syndrome Scale With Data From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)

April 15, 2012

Eric D. A. Hermes, Daniel Sokoloff, T. Scott Stroup, et al

Suicide Attempts and Health-Related Quality of Life

ED Visits for Mental Health Conditions in the US

Post-Discharge Suicide Attempts in Veterans Treated for PTSD

Heterogeneity of Treatment Effects of LAI Antipsychotics

Antipsychotic Prescriptions in Outpatients With MDD

Benzodiazepine Safety: Mortality Risk or Multiple Chronic Disease Comorbidity?

Sleep Disturbance in Chronic Military-Related PTSD: Clinical Impact and Response to Adjunctive Risperidone in the Veterans Affairs Cooperative Study #504

Marijuana Use Is Associated With Worse Outcomes in Symptom Severity and Violent Behavior in Patients With Posttraumatic Stress Disorder

The RAISE: First-Episode Psychosis

Reply to Cost and Cost-Effectiveness in a Randomized Trial of Long-Acting Risperidone for Schizophrenia

Cost and Cost-Effectiveness in a Randomized Trial of Long-Acting Risperidone for Schizophrenia

Minimum Clinically Important Difference in the Positive and Negative Syndrome Scale With Data From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)

ELSEWHERE:

FOLLOW US:

Robert A. Rosenheck, MD

Suicide Attempts and Health-Related Quality of Life

ED Visits for Mental Health Conditions in the US

Post-Discharge Suicide Attempts in Veterans Treated for PTSD

Heterogeneity of Treatment Effects of LAI Antipsychotics

Antipsychotic Prescriptions in Outpatients With MDD

Benzodiazepine Safety: Mortality Risk or Multiple Chronic Disease Comorbidity?

Sleep Disturbance in Chronic Military-Related PTSD: Clinical Impact and Response to Adjunctive Risperidone in the Veterans Affairs Cooperative Study #504

Marijuana Use Is Associated With Worse Outcomes in Symptom Severity and Violent Behavior in Patients With Posttraumatic Stress Disorder

The RAISE: First-Episode Psychosis

Reply to Cost and Cost-Effectiveness in a Randomized Trial of Long-Acting Risperidone for Schizophrenia

Cost and Cost-Effectiveness in a Randomized Trial of Long-Acting Risperidone for Schizophrenia

Minimum Clinically Important Difference in the Positive and Negative Syndrome Scale With Data From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles